The PARAMOUNT phase III trial demonstrated that pemetrexed continuation maintenance significantly reduced the risk of disease progression ( hazard ratio = 0.62 ) and death ( hazard ratio = 0.78 ) versus placebo in patients with advanced nonsquamous non-small-cell lung cancer .